Ramipril
Ramipril (Altace) is an ACE inhibitor used for hypertension, heart failure, and cardiovascular risk reduction after myocardial infarction. It is a prodrug converted in the liver to its active metabolite ramiprilat. The landmark HOPE trial demonstrated a 22% reduction in cardiovascular death, MI, and stroke in high-risk patients. Like all ACE inhibitors, ramipril causes a dry cough in 10–15% of patients due to bradykinin accumulation, and carries a risk of angioedema. It is absolutely contraindicated in pregnancy due to severe fetal toxicity.
Uses & FDA Indications
Ramipril was FDA-approved in 1991 and has accumulated one of the strongest evidence bases of any antihypertensive, anchored by the HOPE trial and subsequent studies. It is considered a first-line agent in patients with hypertension combined with comorbidities including heart failure, post-MI status, chronic kidney disease with proteinuria, or diabetes with microalbuminuria.
FDA-approved indications include: hypertension; heart failure after myocardial infarction; and reduction of risk of MI, stroke, and cardiovascular death in patients aged 55 or older who are at high risk of a major cardiovascular event. This last indication is unique among antihypertensives and reflects the HOPE trial results demonstrating benefit beyond blood pressure reduction.
Off-label uses include chronic kidney disease to reduce proteinuria, diabetic nephropathy, and primary prevention of cardiovascular events in select high-risk patients. The renoprotective effects of ACE inhibitors in proteinuric kidney disease are well-established and guide their preferential use in these populations.
How It Works
Ramipril is a prodrug ester that undergoes hepatic de-esterification to ramiprilat, its pharmacologically active diacid form. Ramiprilat potently and competitively inhibits angiotensin-converting enzyme (ACE), the enzyme responsible for converting angiotensin I to angiotensin II in the renin-angiotensin-aldosterone system (RAAS).
By inhibiting ACE, ramiprilat reduces circulating angiotensin II, leading to vasodilation (reduced systemic vascular resistance), decreased aldosterone secretion (reduced sodium and water retention), and ultimately lower blood pressure. ACE inhibition also prevents the degradation of bradykinin, a vasodilatory peptide. Elevated bradykinin contributes to additional vasodilation and cardioprotective effects — but is also responsible for the class-effect dry cough.
The HOPE (Heart Outcomes Prevention Evaluation) trial randomized over 9,000 patients at high cardiovascular risk to ramipril or placebo for approximately 5 years. Ramipril produced a 22% relative risk reduction in the combined endpoint of MI, stroke, or cardiovascular death. Crucially, these benefits appeared to exceed what could be explained by blood pressure reduction alone, suggesting direct organ-protective effects of RAAS inhibition.
PREGNANCY CONTRAINDICATION (BOXED WARNING): ACE inhibitors including ramipril cause fetal renal tubular dysplasia and neonatal renal failure when used in the second or third trimester. Exposure during the first trimester has also been linked to cardiovascular malformations. Ramipril is absolutely contraindicated throughout pregnancy. Women of childbearing potential must use effective contraception.
Side Effects
Common
- Dry, persistent cough — the most recognizable ACE inhibitor class effect; affects 10–15% of patients; caused by bradykinin accumulation; does not respond to cough suppressants; resolves upon discontinuation
- Hypotension — particularly with first dose; exacerbated by diuretics, volume depletion, or high-dose initiation
- Dizziness, lightheadedness — related to blood pressure lowering
- Hyperkalemia — reduced aldosterone leads to potassium retention; monitor in CKD and with concurrent potassium-raising drugs
- Elevated serum creatinine — expected mild rise; significant elevation warrants workup for renal artery stenosis
- Fatigue, headache
Serious
- Angioedema — potentially life-threatening swelling of the lips, tongue, throat, or larynx. Occurs in <1% of patients but can cause airway obstruction. Risk is higher in Black patients. May occur at any time during therapy, even after years of tolerance. Requires immediate discontinuation and emergency care if airway involvement is suspected.
- Acute kidney injury — in bilateral renal artery stenosis or severe volume depletion; ACE inhibitor-induced reduction of angiotensin II removes the efferent arteriolar constriction that maintains GFR
- Fetal toxicity — see boxed warning; absolutely contraindicated in pregnancy
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| ARBs (valsartan, losartan) / Aliskiren | Dual RAAS blockade increases risk of hypotension, hyperkalemia, and acute kidney injury significantly, without demonstrated additional cardiovascular benefit in most populations. | High — combination generally contraindicated; avoid in diabetes or CKD |
| Potassium Supplements / Potassium-Sparing Diuretics (spironolactone, eplerenone) | Additive hyperkalemia; both mechanisms reduce potassium excretion. Risk is substantially elevated in CKD. | High — monitor potassium closely; avoid unnecessary potassium supplementation |
| NSAIDs (ibuprofen, naproxen, diclofenac) | NSAIDs blunt the antihypertensive and renoprotective effects of ACE inhibitors and increase acute kidney injury risk, especially in volume-depleted patients. | Moderate-High — avoid chronic NSAID use; use acetaminophen when analgesic is needed |
| Lithium | ACE inhibitors reduce renal lithium clearance, increasing plasma lithium to potentially toxic levels. | High — monitor lithium levels closely; consider dose adjustment |
| Sacubitril (Entresto) | Sacubitril also inhibits neprilysin, an enzyme that degrades bradykinin. Combining with an ACE inhibitor dramatically increases bradykinin levels and angioedema risk. | Contraindicated — must wait ≥36 hours after stopping ACE inhibitor before starting sacubitril/valsartan |
Warnings & Contraindications
Contraindications
- Pregnancy — boxed warning; absolute contraindication
- History of angioedema with any ACE inhibitor
- Hereditary or idiopathic angioedema
- Concomitant use with sacubitril/valsartan (Entresto) — requires ≥36-hour washout
- Concomitant use with aliskiren in patients with diabetes
Angioedema
Angioedema is the most feared adverse effect of ACE inhibitors. It can develop at any time during therapy — even after months or years of uneventful use — and involves rapid swelling of the subcutaneous and submucosal tissues, particularly of the face, lips, tongue, and throat. Laryngeal angioedema can be fatal. The mechanism is bradykinin-mediated (unlike allergic angioedema which is histamine-mediated), so antihistamines and epinephrine have limited efficacy. Fresh frozen plasma and icatibant (a bradykinin B2 receptor antagonist) are treatment options. Ramipril must be permanently discontinued; switching to an ARB carries a lower but not zero risk of recurrence.
Renal Considerations
A mild rise in serum creatinine (up to 30%) after starting an ACE inhibitor is expected and generally acceptable — it reflects reduced efferent arteriolar tone and is not a reason to stop the drug in most patients. A larger rise, or a rise accompanied by hyperkalemia, warrants evaluation for bilateral renal artery stenosis and potential discontinuation. ACE inhibitors are generally nephroprotective in proteinuric kidney disease but can precipitate acute kidney injury in hemodynamically compromised patients.
Check for hyperkalemia risk, RAAS interactions, or angioedema history with ramipril.
Check Drug Interactions →Frequently Asked Questions
What is the ACE inhibitor cough from ramipril?
The ACE inhibitor cough is a dry, persistent, nonproductive cough that occurs in approximately 10–15% of patients taking any ACE inhibitor, including ramipril. It is caused by the accumulation of bradykinin and substance P in the lungs — byproducts that ACE normally degrades. When ACE is inhibited, these substances accumulate and irritate airway sensory nerves, triggering the cough reflex. The cough typically appears within the first weeks of therapy, is worse at night, and does not respond to antitussives. It resolves within days to weeks of stopping the drug. Patients who cannot tolerate the cough are typically switched to an ARB (such as valsartan or losartan), which does not affect bradykinin metabolism.
What did the HOPE trial show about ramipril?
The HOPE (Heart Outcomes Prevention Evaluation) trial, published in the New England Journal of Medicine in 2000, was a landmark study of over 9,000 high-risk patients aged 55 or older with cardiovascular disease or diabetes plus one additional risk factor. Patients randomized to ramipril showed a 22% reduction in the combined primary endpoint of myocardial infarction, stroke, or death from cardiovascular causes compared to placebo, over approximately 5 years. Notably, these benefits were observed even in patients who were not hypertensive, suggesting that the cardioprotective effects of ramipril extend beyond blood pressure reduction alone — possibly through anti-inflammatory, anti-proliferative, and endothelial-stabilizing mechanisms.
Is ramipril a prodrug?
Yes. Ramipril is an ester prodrug that must be converted by esterases in the liver to its active form, ramiprilat. Ramipril itself has minimal ACE-inhibiting activity; it is the de-esterified metabolite ramiprilat that exerts the pharmacological effect. This is similar to other ACE inhibitor prodrugs such as enalapril (active form: enalaprilat) and perindopril (active form: perindoprilat). The prodrug design improves oral bioavailability compared to the active diacid form. Because hepatic conversion is required, ramipril should be used with caution in patients with severe hepatic impairment.